Botox v. Reloxin: Market Share Battle May Revive DTC Spending Late in 2009
Botox v. Reloxin: Market Share Battle May Revive DTC Spending Late in 2009
Source: Pharma Marketing Blog (John Mack)
you thought the DTC advertising sleep aid (Lunesta v. AmbienCR v. Rozerem) advertising war was excessive, wait until Reloxin is approved for marketing by the FDA, which may happen during the second half of this year according to Bloomberg.com (see "Medicis's Reloxin May Vie With Botox in U.S. to Clear Wrinkles").
“The results of the study [published in the March/April issue of Archives of Facial Plastic Surgery] show that it’s as good as Botox," Ronald Moy, the lead author of the study and a professor in the medical school at the University of California, Los Angeles, in a March 13 telephone interview. "The side effects are the same as Botox."
“The results of the study [published in the March/April issue of Archives of Facial Plastic Surgery] show that it’s as good as Botox," Ronald Moy, the lead author of the study and a professor in the medical school at the University of California, Los Angeles, in a March 13 telephone interview. "The side effects are the same as Botox."
Click link below to continue:
